| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 18 | 2019 | 316 | 2.740 |
Why?
|
| Anesthetics, Local | 9 | 2016 | 91 | 2.020 |
Why?
|
| Analgesics | 18 | 2022 | 108 | 1.940 |
Why?
|
| Spinal Cord | 13 | 2013 | 104 | 1.660 |
Why?
|
| Rats, Sprague-Dawley | 31 | 2018 | 454 | 1.660 |
Why?
|
| Animals | 64 | 2022 | 4580 | 1.620 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 97 | 1.590 |
Why?
|
| Pain Measurement | 20 | 2016 | 464 | 1.510 |
Why?
|
| Disease Models, Animal | 18 | 2022 | 727 | 1.500 |
Why?
|
| Sciatic Nerve | 8 | 2016 | 32 | 1.430 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2015 | 29 | 1.410 |
Why?
|
| Rats | 38 | 2022 | 859 | 1.360 |
Why?
|
| Nerve Block | 5 | 2016 | 62 | 1.170 |
Why?
|
| Dexamethasone | 6 | 2016 | 48 | 1.150 |
Why?
|
| Bupivacaine | 6 | 2016 | 54 | 1.080 |
Why?
|
| Clonidine | 9 | 2016 | 31 | 1.040 |
Why?
|
| Lidocaine | 6 | 2012 | 40 | 0.990 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 56 | 0.970 |
Why?
|
| Insulin | 2 | 2015 | 92 | 0.910 |
Why?
|
| Osteoarthritis, Knee | 5 | 2016 | 381 | 0.880 |
Why?
|
| Ketamine | 3 | 2019 | 33 | 0.880 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2016 | 37 | 0.830 |
Why?
|
| Pain | 10 | 2013 | 394 | 0.820 |
Why?
|
| Hyperalgesia | 7 | 2022 | 46 | 0.820 |
Why?
|
| Ketorolac | 4 | 2016 | 16 | 0.810 |
Why?
|
| Injections, Spinal | 17 | 2018 | 49 | 0.790 |
Why?
|
| Behavior, Animal | 8 | 2019 | 106 | 0.780 |
Why?
|
| Neuralgia | 3 | 2019 | 16 | 0.780 |
Why?
|
| Morphine | 11 | 2016 | 81 | 0.780 |
Why?
|
| Male | 58 | 2022 | 15649 | 0.780 |
Why?
|
| Arthralgia | 5 | 2018 | 121 | 0.750 |
Why?
|
| Ganglia, Spinal | 6 | 2022 | 57 | 0.720 |
Why?
|
| gamma-Aminobutyric Acid | 8 | 2011 | 49 | 0.710 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2009 | 15 | 0.710 |
Why?
|
| Electrodes, Implanted | 3 | 2018 | 46 | 0.680 |
Why?
|
| Analgesics, Opioid | 10 | 2016 | 217 | 0.670 |
Why?
|
| Laparotomy | 2 | 2016 | 21 | 0.650 |
Why?
|
| Vancomycin | 1 | 2018 | 57 | 0.640 |
Why?
|
| Mice | 15 | 2022 | 1620 | 0.620 |
Why?
|
| Glucocorticoids | 2 | 2016 | 68 | 0.610 |
Why?
|
| Amides | 2 | 2010 | 21 | 0.610 |
Why?
|
| Baclofen | 8 | 1993 | 15 | 0.610 |
Why?
|
| Analgesia | 4 | 2016 | 38 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 7 | 2022 | 432 | 0.580 |
Why?
|
| Triamcinolone | 1 | 2016 | 5 | 0.570 |
Why?
|
| Blood Patch, Epidural | 2 | 2008 | 9 | 0.550 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 59 | 0.540 |
Why?
|
| Oxygen | 1 | 2016 | 85 | 0.540 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 83 | 0.540 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 79 | 0.540 |
Why?
|
| Cytokines | 4 | 2015 | 349 | 0.540 |
Why?
|
| Motor Activity | 9 | 2017 | 369 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 402 | 0.520 |
Why?
|
| Time Factors | 14 | 2016 | 1621 | 0.520 |
Why?
|
| Osteoarthritis | 6 | 2018 | 363 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 29 | 0.510 |
Why?
|
| General Surgery | 1 | 2015 | 49 | 0.500 |
Why?
|
| Blood Glucose | 1 | 2015 | 112 | 0.490 |
Why?
|
| Octreotide | 5 | 1997 | 7 | 0.460 |
Why?
|
| Complex Regional Pain Syndromes | 3 | 2020 | 25 | 0.460 |
Why?
|
| Spinal Puncture | 4 | 2022 | 27 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2012 | 440 | 0.450 |
Why?
|
| Female | 36 | 2022 | 16224 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 176 | 0.440 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 295 | 0.430 |
Why?
|
| Pain, Intractable | 4 | 2007 | 15 | 0.420 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 1113 | 0.420 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2008 | 34 | 0.410 |
Why?
|
| Intracranial Pressure | 2 | 2002 | 21 | 0.410 |
Why?
|
| Nociceptors | 2 | 2010 | 19 | 0.400 |
Why?
|
| Cyclooxygenase 2 | 3 | 2008 | 31 | 0.400 |
Why?
|
| Injections | 5 | 2016 | 56 | 0.390 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2022 | 15 | 0.390 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 13 | 0.380 |
Why?
|
| Pain Threshold | 2 | 2016 | 21 | 0.380 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2007 | 14 | 0.380 |
Why?
|
| Amines | 3 | 2007 | 15 | 0.380 |
Why?
|
| Muscle, Skeletal | 3 | 2015 | 349 | 0.380 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 14 | 0.380 |
Why?
|
| Dinoprostone | 3 | 2007 | 30 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2016 | 101 | 0.370 |
Why?
|
| Random Allocation | 5 | 2020 | 146 | 0.370 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2009 | 33 | 0.370 |
Why?
|
| Epinephrine | 4 | 2012 | 35 | 0.370 |
Why?
|
| Infusion Pumps | 8 | 1993 | 16 | 0.360 |
Why?
|
| Posterior Horn Cells | 2 | 2013 | 4 | 0.350 |
Why?
|
| Wound Healing | 1 | 2010 | 168 | 0.350 |
Why?
|
| Analgesia, Epidural | 3 | 2007 | 58 | 0.340 |
Why?
|
| Knee Joint | 3 | 2016 | 797 | 0.340 |
Why?
|
| Hematoma, Subdural, Intracranial | 1 | 2008 | 3 | 0.340 |
Why?
|
| Subdural Effusion | 1 | 2008 | 7 | 0.340 |
Why?
|
| Phantom Limb | 1 | 2008 | 4 | 0.330 |
Why?
|
| Memantine | 1 | 2008 | 13 | 0.330 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2006 | 26 | 0.330 |
Why?
|
| Intervertebral Disc Degeneration | 3 | 2018 | 116 | 0.330 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 6 | 0.320 |
Why?
|
| Humans | 49 | 2018 | 29393 | 0.320 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 88 | 0.320 |
Why?
|
| Brain | 6 | 2010 | 1687 | 0.320 |
Why?
|
| Arthritis, Experimental | 3 | 2015 | 125 | 0.310 |
Why?
|
| Muscle Spasticity | 6 | 1993 | 16 | 0.310 |
Why?
|
| Globus Pallidus | 4 | 2000 | 31 | 0.310 |
Why?
|
| Isoenzymes | 2 | 2004 | 51 | 0.300 |
Why?
|
| Microglia | 1 | 2008 | 124 | 0.300 |
Why?
|
| Treatment Outcome | 7 | 2019 | 3478 | 0.300 |
Why?
|
| Arachnoiditis | 1 | 2005 | 5 | 0.270 |
Why?
|
| Cauda Equina | 1 | 2005 | 6 | 0.270 |
Why?
|
| Chondrocytes | 3 | 2011 | 197 | 0.260 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 5 | 2009 | 30 | 0.260 |
Why?
|
| Hemodynamics | 2 | 2003 | 84 | 0.260 |
Why?
|
| Middle Aged | 22 | 2018 | 9830 | 0.260 |
Why?
|
| Infusion Pumps, Implantable | 6 | 2000 | 13 | 0.250 |
Why?
|
| Protein Kinase C-delta | 2 | 2016 | 11 | 0.240 |
Why?
|
| Central Nervous System | 4 | 2018 | 56 | 0.240 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2011 | 696 | 0.240 |
Why?
|
| Substantia Gelatinosa | 2 | 1993 | 2 | 0.240 |
Why?
|
| Low Back Pain | 2 | 2018 | 139 | 0.230 |
Why?
|
| Up-Regulation | 5 | 2008 | 174 | 0.230 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 284 | 0.230 |
Why?
|
| Magnesium Sulfate | 2 | 2000 | 8 | 0.220 |
Why?
|
| Neutrophils | 2 | 2016 | 117 | 0.220 |
Why?
|
| Ion Channels | 1 | 2004 | 189 | 0.210 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 223 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2013 | 42 | 0.210 |
Why?
|
| Dogs | 6 | 2013 | 254 | 0.200 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2009 | 23 | 0.200 |
Why?
|
| Lactones | 3 | 2007 | 14 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2016 | 483 | 0.200 |
Why?
|
| Dystonia | 2 | 2000 | 53 | 0.200 |
Why?
|
| Neoplasms | 4 | 2010 | 248 | 0.190 |
Why?
|
| Hydrocephalus | 1 | 2000 | 25 | 0.190 |
Why?
|
| Drug Combinations | 3 | 2016 | 83 | 0.190 |
Why?
|
| Aged | 14 | 2015 | 9450 | 0.180 |
Why?
|
| Brain Injuries | 1 | 2000 | 47 | 0.180 |
Why?
|
| Fetal Development | 1 | 2019 | 3 | 0.180 |
Why?
|
| Spinal Cord Diseases | 2 | 1992 | 51 | 0.180 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 5 | 0.180 |
Why?
|
| Huntington Disease | 1 | 2000 | 60 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2000 | 93 | 0.180 |
Why?
|
| Neurogenesis | 1 | 2019 | 13 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 24 | 0.180 |
Why?
|
| Adult | 17 | 2015 | 8618 | 0.180 |
Why?
|
| Metformin | 1 | 2020 | 21 | 0.180 |
Why?
|
| Edema | 1 | 2020 | 38 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 32 | 0.180 |
Why?
|
| Anesthetics | 1 | 2019 | 26 | 0.180 |
Why?
|
| Axons | 3 | 2016 | 37 | 0.170 |
Why?
|
| Multiple Sclerosis | 3 | 1996 | 87 | 0.170 |
Why?
|
| Rodentia | 1 | 2018 | 6 | 0.170 |
Why?
|
| Skin | 2 | 2010 | 117 | 0.170 |
Why?
|
| Cartilage, Articular | 3 | 2012 | 524 | 0.170 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2018 | 8 | 0.160 |
Why?
|
| Acute Pain | 1 | 2018 | 21 | 0.160 |
Why?
|
| Tibial Nerve | 3 | 2008 | 7 | 0.160 |
Why?
|
| Sulfones | 3 | 2007 | 24 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 32 | 0.160 |
Why?
|
| Stereotaxic Techniques | 5 | 2000 | 27 | 0.150 |
Why?
|
| Dopamine | 3 | 1996 | 156 | 0.150 |
Why?
|
| Wound Closure Techniques | 1 | 2016 | 9 | 0.150 |
Why?
|
| Chicago | 3 | 2015 | 865 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 2 | 2012 | 28 | 0.140 |
Why?
|
| Buprenorphine | 1 | 2016 | 5 | 0.140 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2016 | 3 | 0.140 |
Why?
|
| Pain Management | 1 | 2018 | 143 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 31 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 38 | 0.140 |
Why?
|
| Parasympatholytics | 1 | 1996 | 14 | 0.140 |
Why?
|
| Sympatholytics | 1 | 1996 | 14 | 0.140 |
Why?
|
| Muscular Dystrophies | 1 | 1996 | 2 | 0.140 |
Why?
|
| Intracranial Hypotension | 2 | 2008 | 7 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 161 | 0.140 |
Why?
|
| Injections, Intra-Articular | 1 | 2016 | 88 | 0.140 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 2 | 0.140 |
Why?
|
| Joints | 2 | 2016 | 97 | 0.140 |
Why?
|
| Herpes Zoster | 1 | 2015 | 4 | 0.140 |
Why?
|
| Neostigmine | 2 | 2007 | 6 | 0.130 |
Why?
|
| Streptozocin | 1 | 2015 | 6 | 0.130 |
Why?
|
| Drug Synergism | 4 | 2004 | 64 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2015 | 16 | 0.130 |
Why?
|
| Models, Animal | 3 | 2016 | 126 | 0.130 |
Why?
|
| Age Distribution | 1 | 2015 | 94 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2015 | 67 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2015 | 87 | 0.130 |
Why?
|
| Drug Overdose | 1 | 1995 | 8 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2015 | 100 | 0.130 |
Why?
|
| Cerebrospinal Fluid | 1 | 1995 | 18 | 0.130 |
Why?
|
| Drainage | 1 | 1995 | 50 | 0.120 |
Why?
|
| Pregabalin | 5 | 2011 | 22 | 0.120 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 281 | 0.120 |
Why?
|
| Incidence | 2 | 2015 | 756 | 0.120 |
Why?
|
| Spinal Cord Injuries | 4 | 1993 | 47 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2015 | 1818 | 0.120 |
Why?
|
| Young Adult | 3 | 2015 | 1935 | 0.120 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2010 | 14 | 0.120 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 669 | 0.120 |
Why?
|
| Receptors, GABA | 1 | 1993 | 5 | 0.120 |
Why?
|
| Brain Mapping | 2 | 2010 | 195 | 0.120 |
Why?
|
| Decerebrate State | 1 | 1993 | 1 | 0.120 |
Why?
|
| Hydromorphone | 1 | 1993 | 3 | 0.120 |
Why?
|
| Receptors, GABA-B | 1 | 1993 | 3 | 0.120 |
Why?
|
| Isoflurane | 2 | 2019 | 9 | 0.120 |
Why?
|
| Neurons | 4 | 2019 | 374 | 0.120 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 504 | 0.120 |
Why?
|
| Down-Regulation | 1 | 1993 | 112 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2012 | 5 | 0.110 |
Why?
|
| Implants, Experimental | 1 | 2012 | 31 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 22 | 0.110 |
Why?
|
| Spasm | 1 | 1992 | 7 | 0.110 |
Why?
|
| Paralysis | 2 | 2008 | 19 | 0.110 |
Why?
|
| Hospitalization | 1 | 2015 | 317 | 0.110 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 15 | 0.100 |
Why?
|
| Substance P | 1 | 2011 | 18 | 0.100 |
Why?
|
| Norepinephrine | 1 | 2011 | 20 | 0.100 |
Why?
|
| Osteoarthritis, Spine | 1 | 2011 | 7 | 0.100 |
Why?
|
| Glutamic Acid | 1 | 2011 | 32 | 0.100 |
Why?
|
| Cisterna Magna | 2 | 2002 | 7 | 0.100 |
Why?
|
| Biomarkers | 1 | 2015 | 693 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 3 | 1999 | 173 | 0.100 |
Why?
|
| Cisplatin | 4 | 1988 | 91 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 364 | 0.100 |
Why?
|
| Brain Neoplasms | 4 | 1988 | 124 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2009 | 864 | 0.100 |
Why?
|
| Zygapophyseal Joint | 1 | 2011 | 44 | 0.100 |
Why?
|
| Back Pain | 1 | 2011 | 63 | 0.100 |
Why?
|
| Vocalization, Animal | 2 | 2013 | 5 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 391 | 0.100 |
Why?
|
| Peripheral Nerves | 2 | 2008 | 20 | 0.100 |
Why?
|
| Neural Pathways | 1 | 2011 | 83 | 0.090 |
Why?
|
| Adrenergic Agonists | 1 | 2010 | 5 | 0.090 |
Why?
|
| Sensation | 1 | 2010 | 17 | 0.090 |
Why?
|
| Palliative Care | 1 | 1992 | 145 | 0.090 |
Why?
|
| Electric Stimulation Therapy | 2 | 2008 | 44 | 0.090 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 55 | 0.090 |
Why?
|
| Intervertebral Disc | 1 | 2011 | 212 | 0.090 |
Why?
|
| Heart Rate | 2 | 2003 | 144 | 0.090 |
Why?
|
| Arteries | 1 | 1989 | 17 | 0.090 |
Why?
|
| Nerve Growth Factors | 3 | 1999 | 44 | 0.080 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 1989 | 39 | 0.080 |
Why?
|
| Synovial Membrane | 3 | 2016 | 81 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2013 | 495 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 107 | 0.080 |
Why?
|
| Substantia Nigra | 3 | 1996 | 148 | 0.080 |
Why?
|
| Lumbosacral Region | 2 | 2005 | 69 | 0.080 |
Why?
|
| Risk Factors | 1 | 2015 | 2447 | 0.080 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2008 | 16 | 0.080 |
Why?
|
| Body Weight | 2 | 2003 | 133 | 0.080 |
Why?
|
| Headache Disorders | 1 | 2008 | 3 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 44 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2018 | 140 | 0.080 |
Why?
|
| Subarachnoid Space | 4 | 1989 | 8 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 1988 | 21 | 0.080 |
Why?
|
| Recurrence | 1 | 2008 | 350 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 1996 | 39 | 0.080 |
Why?
|
| Terrorism | 1 | 2007 | 13 | 0.080 |
Why?
|
| Anesthesia, Spinal | 1 | 1987 | 18 | 0.080 |
Why?
|
| Spinal Nerve Roots | 1 | 1987 | 29 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 42 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2007 | 135 | 0.070 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2006 | 9 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 150 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2007 | 188 | 0.070 |
Why?
|
| Interleukins | 1 | 2006 | 37 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 487 | 0.070 |
Why?
|
| Tissue Adhesions | 1 | 2005 | 13 | 0.070 |
Why?
|
| Rabbits | 3 | 2013 | 283 | 0.070 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 34 | 0.070 |
Why?
|
| Neuroma | 1 | 2005 | 4 | 0.060 |
Why?
|
| Neuroglia | 2 | 2018 | 39 | 0.060 |
Why?
|
| Nerve Transfer | 1 | 2005 | 4 | 0.060 |
Why?
|
| Thoracotomy | 1 | 2004 | 22 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2004 | 3 | 0.060 |
Why?
|
| Colforsin | 1 | 2004 | 10 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2004 | 21 | 0.060 |
Why?
|
| Reaction Time | 4 | 1997 | 123 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2008 | 349 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 213 | 0.060 |
Why?
|
| Reflex | 1 | 1984 | 3 | 0.060 |
Why?
|
| Indans | 1 | 2004 | 10 | 0.060 |
Why?
|
| Acetates | 1 | 2003 | 19 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 16 | 0.060 |
Why?
|
| Autoradiography | 2 | 1993 | 11 | 0.060 |
Why?
|
| Yohimbine | 2 | 1996 | 9 | 0.060 |
Why?
|
| Foot | 1 | 2003 | 30 | 0.060 |
Why?
|
| Injections, Intraventricular | 3 | 1996 | 13 | 0.060 |
Why?
|
| Fentanyl | 1 | 2003 | 23 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2018 | 395 | 0.060 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 8 | 0.060 |
Why?
|
| Magnesium | 1 | 2003 | 47 | 0.060 |
Why?
|
| Body Temperature | 1 | 2003 | 59 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 20 | 0.060 |
Why?
|
| Exploratory Behavior | 2 | 2016 | 18 | 0.060 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 6 | 0.060 |
Why?
|
| Mammals | 1 | 2022 | 26 | 0.050 |
Why?
|
| Injections, Epidural | 1 | 2002 | 17 | 0.050 |
Why?
|
| Epidural Space | 1 | 2002 | 24 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2004 | 288 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 76 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2007 | 957 | 0.050 |
Why?
|
| Pregnancy | 2 | 2019 | 405 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2009 | 504 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 241 | 0.050 |
Why?
|
| Corpus Striatum | 2 | 1994 | 111 | 0.050 |
Why?
|
| Blood Pressure | 2 | 1996 | 241 | 0.050 |
Why?
|
| Sex Factors | 1 | 2003 | 496 | 0.050 |
Why?
|
| Glioma | 3 | 1988 | 47 | 0.050 |
Why?
|
| Axonal Transport | 2 | 1999 | 8 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 216 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2015 | 108 | 0.050 |
Why?
|
| Telemetry | 1 | 2000 | 11 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2000 | 59 | 0.050 |
Why?
|
| Inflammation | 2 | 2013 | 345 | 0.050 |
Why?
|
| Proteoglycans | 2 | 2012 | 337 | 0.050 |
Why?
|
| Microsurgery | 1 | 2000 | 40 | 0.050 |
Why?
|
| Adolescent | 2 | 2010 | 2280 | 0.050 |
Why?
|
| Tibial Fractures | 1 | 2020 | 13 | 0.050 |
Why?
|
| Propofol | 1 | 2019 | 17 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2011 | 676 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 105 | 0.040 |
Why?
|
| Cerebral Cortex | 2 | 1996 | 195 | 0.040 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 1999 | 3 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1990 | 53 | 0.040 |
Why?
|
| Parkinson Disease | 2 | 1998 | 1164 | 0.040 |
Why?
|
| Spine | 1 | 2000 | 121 | 0.040 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2011 | 26 | 0.040 |
Why?
|
| Nucleus Pulposus | 1 | 2018 | 12 | 0.040 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Muscimol | 1 | 1998 | 1 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2018 | 29 | 0.040 |
Why?
|
| GABA Agonists | 1 | 1998 | 3 | 0.040 |
Why?
|
| Rats, Inbred F344 | 3 | 2008 | 48 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2000 | 792 | 0.040 |
Why?
|
| CLOCK Proteins | 1 | 2018 | 26 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 250 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 1999 | 117 | 0.040 |
Why?
|
| Somatostatin | 1 | 1997 | 5 | 0.040 |
Why?
|
| Limbic System | 1 | 1996 | 11 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1997 | 22 | 0.040 |
Why?
|
| Dioxanes | 1 | 1996 | 3 | 0.040 |
Why?
|
| Idazoxan | 1 | 1996 | 3 | 0.040 |
Why?
|
| Vagus Nerve | 1 | 1996 | 14 | 0.030 |
Why?
|
| Glycopyrrolate | 1 | 1996 | 5 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 1989 | 42 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1996 | 9 | 0.030 |
Why?
|
| Receptor, trkA | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sensory Receptor Cells | 1 | 2016 | 7 | 0.030 |
Why?
|
| Gait | 2 | 2013 | 404 | 0.030 |
Why?
|
| Neostriatum | 1 | 1996 | 22 | 0.030 |
Why?
|
| Bradycardia | 1 | 1996 | 28 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2015 | 5 | 0.030 |
Why?
|
| Muscle Tonus | 2 | 1987 | 3 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 22 | 0.030 |
Why?
|
| Nerve Growth Factor | 1 | 2016 | 31 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2008 | 1833 | 0.030 |
Why?
|
| Infusions, Parenteral | 3 | 1996 | 13 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1996 | 323 | 0.030 |
Why?
|
| Wakefulness | 1 | 1996 | 80 | 0.030 |
Why?
|
| Imidazoles | 1 | 1996 | 72 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 109 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 66 | 0.030 |
Why?
|
| Rotarod Performance Test | 1 | 2013 | 8 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2013 | 63 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 383 | 0.030 |
Why?
|
| Horses | 1 | 2013 | 19 | 0.030 |
Why?
|
| Sheep | 1 | 2013 | 39 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 47 | 0.030 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 1993 | 6 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 1993 | 11 | 0.030 |
Why?
|
| Range of Motion, Articular | 2 | 2009 | 699 | 0.030 |
Why?
|
| Kinetics | 1 | 1993 | 225 | 0.030 |
Why?
|
| Skin Physiological Phenomena | 1 | 1992 | 3 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2012 | 17 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 22 | 0.030 |
Why?
|
| Species Specificity | 1 | 2012 | 70 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 1993 | 106 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 65 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2011 | 12 | 0.030 |
Why?
|
| Cattle | 1 | 2011 | 218 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2011 | 159 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2011 | 107 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1992 | 82 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 1997 | 251 | 0.020 |
Why?
|
| Adrenal Medulla | 1 | 1991 | 31 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 125 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 26 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 304 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 36 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2010 | 13 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 39 | 0.020 |
Why?
|
| Cold Temperature | 2 | 2004 | 18 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1939 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1989 | 325 | 0.020 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2009 | 2 | 0.020 |
Why?
|
| Interleukin-18 Receptor beta Subunit | 1 | 2009 | 2 | 0.020 |
Why?
|
| Chemokine CCL20 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2009 | 3 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2009 | 25 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1987 | 184 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 1989 | 195 | 0.020 |
Why?
|
| Wallerian Degeneration | 1 | 2008 | 2 | 0.020 |
Why?
|
| Muscular Atrophy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2008 | 13 | 0.020 |
Why?
|
| Denervation | 1 | 2008 | 21 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 1988 | 6 | 0.020 |
Why?
|
| Extracellular Space | 1 | 1988 | 13 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1988 | 23 | 0.020 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2007 | 11 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 53 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1987 | 10 | 0.020 |
Why?
|
| Sleep | 1 | 2009 | 313 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 168 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 78 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2008 | 327 | 0.020 |
Why?
|
| Muscle Rigidity | 1 | 1985 | 26 | 0.020 |
Why?
|
| Cerebellum | 2 | 1983 | 57 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 678 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 66 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 789 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1996 | 83 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2005 | 6 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2005 | 14 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2004 | 12 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2004 | 11 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1987 | 218 | 0.020 |
Why?
|
| Ribs | 1 | 2004 | 15 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2007 | 189 | 0.020 |
Why?
|
| Weight Gain | 1 | 2004 | 66 | 0.020 |
Why?
|
| Hindlimb | 1 | 1984 | 23 | 0.020 |
Why?
|
| Dyssomnias | 1 | 2003 | 8 | 0.010 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2003 | 18 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1984 | 46 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1985 | 167 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1984 | 83 | 0.010 |
Why?
|
| Synapses | 1 | 1984 | 50 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2003 | 64 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2003 | 52 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1983 | 7 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1983 | 75 | 0.010 |
Why?
|
| Hip Joint | 1 | 2007 | 367 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 1251 | 0.010 |
Why?
|
| Aging | 1 | 1992 | 1594 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 173 | 0.010 |
Why?
|
| Platinum | 1 | 1982 | 5 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1982 | 56 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1999 | 1222 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 4851 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1999 | 29 | 0.010 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1999 | 4 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1999 | 8 | 0.010 |
Why?
|
| Extremities | 1 | 1999 | 31 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 129 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 3275 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1998 | 5 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1998 | 12 | 0.010 |
Why?
|
| Naloxone | 1 | 1998 | 12 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 1998 | 14 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1998 | 68 | 0.010 |
Why?
|
| Hemiplegia | 1 | 1998 | 8 | 0.010 |
Why?
|
| Language Disorders | 1 | 1998 | 10 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1998 | 28 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 36 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1998 | 36 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1998 | 91 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1997 | 10 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 7 | 0.010 |
Why?
|
| Occipital Lobe | 1 | 1996 | 13 | 0.010 |
Why?
|
| Biological Transport | 1 | 1996 | 43 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 46 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 1996 | 81 | 0.010 |
Why?
|
| Tremor | 1 | 1998 | 141 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1998 | 129 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1996 | 26 | 0.010 |
Why?
|
| Turkeys | 1 | 1994 | 1 | 0.010 |
Why?
|
| Child | 1 | 1999 | 1346 | 0.010 |
Why?
|
| Antibodies | 1 | 1994 | 65 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 130 | 0.010 |
Why?
|
| Catheterization | 1 | 1988 | 51 | 0.000 |
Why?
|
| Catheters, Indwelling | 1 | 1987 | 25 | 0.000 |
Why?
|
| Cerebral Palsy | 1 | 1985 | 9 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1985 | 56 | 0.000 |
Why?
|
| Muscles | 1 | 1985 | 73 | 0.000 |
Why?
|
| Electromyography | 1 | 1985 | 78 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1985 | 147 | 0.000 |
Why?
|
| Research Design | 1 | 1985 | 213 | 0.000 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1983 | 1 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1983 | 23 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 770 | 0.000 |
Why?
|